Waypoint Backs RxActuator's Push to Move Veterinary Infusion Out of the Clinic

Jeff Journey acquired a veterinary infusion technology before asking investors to help put it back into circulation. Now the founder and CEO of RxActuator is rebuilding the business around a device that can accompany a stable animal home, carrying part of a treatment plan beyond the clinic door.

The Raleigh, North Carolina company announced an undisclosed seed investment from Waypoint Ventures on October 15, 2026. The check anchors the seed round and supports the Mini-Infuser's commercial relaunch, which began October 1. Manufacturing and veterinary adoption are central to the spending plan, alongside additional specialty protocols and future intelligent infusion technology. Neither the size of the investment nor a valuation was disclosed, and the release left the full round's completion and any additional investors unspecified.

The commercial case turns on a specific clinical moment: a patient may be stable enough to leave the hospital while still needing continuous medication. RxActuator wants its wearable to make that combination practical. Whether the opportunity materializes depends on veterinarians being able to carry a supervised care plan into the home as reliably as they can dispense the equipment.

The Mini-Infuser uses a water-activated polymer actuator rather than an electronic motor. RxActuator describes a wearable, single-use system designed to deliver 10 mL of medication subcutaneously over 48 hours. The absence of batteries and software is part of the current design; intelligent infusion appears in development plans rather than as a capability the product already delivers. Advertised applications span postoperative and chronic pain, hospice and palliative care, and antibiotics.

Adoption will involve more than adding an item to inventory. Veterinarians need protocols they can apply to the patient in front of them and a clear explanation for the owner taking that patient home. The company reports that more than 500 units have been used by over 90 veterinary clinics in three countries, with most volume from repeat accounts — company-reported cumulative figures with no independently verified revenue or retention data, describing an existing audience rather than sales since October 1.

The clinical evidence is bounded. A 2025 Journal of Veterinary Internal Medicine study led by Caylen Erger enrolled 19 dogs in a non-blinded, single-arm outpatient pancreatitis protocol combining several treatments with wearable infusion. Seventeen dogs remained outpatients and two were hospitalized; only 10 met the study's higher laboratory threshold for the suspected-pancreatitis subgroup. The authors said the design could not isolate individual treatments or establish the protocol's efficacy relative to inpatient care. CEVA Animal Health funded the study, and devices were provided at reduced cost.